|
gptkbp:instanceOf
|
gptkb:drug
GLP-1 receptor agonist
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A10BJ04
|
|
gptkbp:brand
|
gptkb:Tanzeum
gptkb:Eperzan
|
|
gptkbp:CASNumber
|
850876-88-9
|
|
gptkbp:connectsTo
|
gptkb:human_albumin
|
|
gptkbp:contains
|
two tandem copies of modified human GLP-1
|
|
gptkbp:contraindication
|
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
personal or family history of medullary thyroid carcinoma
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:eliminatedIn
|
renal and proteolytic degradation
|
|
gptkbp:halfLife
|
~5 days
|
|
gptkbp:hasMolecularFormula
|
C256H381N65O76S6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
albiglutide
|
|
gptkbp:mechanismOfAction
|
GLP-1 receptor agonist
|
|
gptkbp:product
|
gptkb:protein
|
|
gptkbp:retired
|
commercial reasons
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
nausea
diarrhea
injection site reaction
hypoglycemia (with insulin or sulfonylurea)
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes
|
|
gptkbp:withdrawn
|
2018
|
|
gptkbp:bfsParent
|
gptkb:GLP-1_receptor_agonists
|
|
gptkbp:bfsLayer
|
6
|